Who Paid My Doc
Thomas Campbell
Infectious Disease Aurora, CO Medical Doctor
NPI 1447340120 CMS profile 19978
12605 E 16Th Ave, Anschutz Pavilion, Aurora, CO 80045
General payments
$10,705
Research payments
$1,591
Ownership & investment interest
$0
Research they led as principal investigator
$4,194,954
Through program year 2024, Thomas Campbell of Aurora, CO is reported in the CMS Open Payments database as having received $10,705 across 10 general payments and $1,591 in research payments paid to them. Separately, studies naming them as principal investigator received $4,194,954 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 88th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | Research | $1,591 | 13 | |
| 2020 | General | $3,680 | 1 | |
| 2019 | General | $7,025 | 9 |
Beside peers
- Thomas Campbell
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Thomas Campbell were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Thomas Campbell | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $7,025 | $190 | $60–$862 | $163 |
| 2020 | $3,680 | $124 | $32–$606 | $114 |
| 2021 | $0 | $148 | $38–$905 | $132 |
| 2022 | $0 | $166 | $50–$834 | $149 |
| 2023 | $0 | $171 | $57–$787 | $160 |
| 2024 | $0 | $176 | $52–$752 | $164 |
| 2025 | $0 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 27 drugsPart D claims
422
Drug cost
$424,163
Branded share of claims
49.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 32 | $122,143 | |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | Brand | 16 | $95,261 | |
| Prezcobix Darunavir/Cobicistat | Brand | 24 | $56,306 | |
| Tivicay Dolutegravir Sodium | Brand | 23 | $50,318 | |
| Isentress Raltegravir Potassium | Brand | 12 | $23,490 | |
| Vemlidy Tenofovir Alafenamide | Brand | 11 | $15,601 | |
| Etravirine | Generic | 12 | $14,478 | |
| Atazanavir Sulfate | Generic | 16 | $13,206 | |
| Darunavir | Generic | 12 | $10,727 | |
| Ritonavir | Generic | 16 | $5,253 |
The 10 drugs with the highest cost, of 27 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$16,472
Medicare patients
56
Services billed
202
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Chronic kidney disease | 75% | |
| Diabetes | 64% | |
| Ischemic heart disease | 48% | |
| Arthritis | 46% | |
| Heart failure | 38% | |
| Atrial fibrillation | 32% | |
| Osteoporosis | 32% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
23 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in Colorado
David Griffith
Infectious Disease · Denver, CO
Kenneth Greenberg
Infectious Disease · Denver, CO
Shannon Kasperbauer
Infectious Disease · Denver, CO
Kristine Erlandson
Infectious Disease · Aurora, CO
Adriana Weinberg
Infectious Disease · Aurora, CO
Carlos Franco Paredes
Infectious Disease · Aurora, CO
Related records
Infectious Disease in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.